For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Fremanezumab - Migraine (prevention)
PAD Profile : Fremanezumab - Migraine (prevention)
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
- Botulinum toxin type A
- Flunarizine dihydrochloride
- Pizotifen malate
- Erenumab
- Galcanezumab
- Propranolol hydrochloride
- Topiramate
- Amitriptyline hydrochloride
- Gabapentin
- Pregabalin
- Rimegepant
- Candesartan cilexetil
- Clonidine hydrochloride
Other Indications
No indications returned.
Additional Documents
Committee Recommendations
The Surrey Heartlands Area Prescribing Committee agreed to adopt the South West London (SWL) migraine prophylaxis drug pathway for chronic and episodic migraine.
NOTE: updates and new additions to the pathway are provided in addendums at the end of the document.
See the Migraine (prophylaxis) Drug Pathway for full information.
The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends fremanezumab as a treatment option for preventing migraine in line with NICE TA764
Fremanezumab will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA764.
Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.